ASCO 2023 | Advancing prostate cancer diagnosis with PSMA PET: opportunities and cautions

Ravi Amrit Madan, MD, from the National Cancer Institute, Bethesda, MD, discusses the emerging era in prostate cancer diagnosis using PSMA PET technology, particularly in defining metastatic disease in newly diagnosed patients. This technology helps spare patients unnecessary side effects of aggressive treatments. However, Dr Madan highlights a concern in applying this approach to patients with recurrent prostate cancer. Although advanced PET imaging can identify microscopic and potentially insignificant disease, there’s no established treatment protocol for these cases. Patients are often categorized based on trial results that were originally designed for different criteria. Dr Madan emphasizes the need for caution, as escalating treatments without sufficient data may lead to increased toxicity. To address these gaps, the National Cancer Institute is launching a trial to monitor the natural history of prostate cancer in patients with positive PSMA PET findings and negative conventional imaging. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.